CSIMarket Company Name, Ticker, Customers, else..
 
Soligenix inc   (NASDAQ: SNGX)
 
Price: $0.3649 $0.00 1.361%
Day's High: $0.3736000061035156 Week Perf: -3.97 %
Day's Low: $ 0.36 30 Day Perf: -6.44 %
Volume (M): 92,370 52 Wk High: $ 2.92
Volume (M$): $ 0 52 Wk Avg: $1.02
Open: $0.36 52 Wk Low: $0.28



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 16
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Soligenix, Inc. is a biopharmaceutical company that focuses on developing and commercializing products to treat rare diseases with unmet medical needs. The company primarily works on developing therapies for areas such as inflammation, oncology, and infectious diseases. Soligenix's main product candidates include a vaccine for the prevention of ricin toxin exposure (RiVax®), a treatment for oral mucositis in head and neck cancer patients (SGX942), and a treatment for pediatric Crohn's disease (SGX203). The company also has a proprietary technology platform called Dusquetide, which enhances the efficacy of existing drugs. Soligenix is headquartered in Princeton, New Jersey, and was founded in 198


   Company Address: 29 EMMONS DRIVE PRINCETON, 8540 NJ
   Company Phone Number: 538-8200   Stock Exchange / Ticker: NASDAQ SNGX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AXSM        7.55% 
EBS   -3.05%    
IONS   -5.21%    
OPK   -4.97%    
SRPT   -11.2%    
VRTX   -8.07%    
• View Complete Report
   



Stocks on the Move

Soligenix Secures Exciting Results for HyBryte in CTCL Study, Boosting Valuation to $35

Published Tue, Jul 16 2024 8:41 AM UTC

Soligenix Inc. (NASDAQ:SNGX) recently unveiled positive interim results from an investigator-initiated study involving HyBryte, a potential treatment for Cutaneous T-Cell Lymphoma (CTCL). The encouraging findings have propelled the company s valuation to an impressive $35, reflecting the market s optimism towards Soligenix s groundbreaking research.The study, which evaluated...
Stocks on the Move

Soligenix Inc A Promising Outlook and Positive Study Results Propelling Growth in the Pharmaceutical Industry

Published Fri, Jun 28 2024 4:55 AM UTC

In the dynamic landscape of the pharmaceutical industry, Soligenix Inc (NASDAQ: SNGX) has emerged as a prominent player, garnering attention from industry analysts and investors alike. This article explores recent developments surrounding Soligenix Inc, including a positive growth outlook and groundbreaking study results that are propelling the company forward. With a focus ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.88
PEG (TTM) -

Financial Strength Current
Quick Ratio -
Working Capital Ratio 2.77
Leverage Ratio (MRQ) 0.58
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.54 $
Revenues (TTM) -
Cash Flow (TTM) 0.06 $
Cash -
Book Value 0.42 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -710,997
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.